We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Read MoreHide Full Article
Key Takeaways
Alvotech's H1 2025 product revenues soared over 200% year over year to nearly $205 million.
Teva and Stada alliances powered the rapid uptake of Humira and Stelara biosimilars across the U.S. and EU.
New approvals and deals extend Alvotech's pipeline into ophthalmology, neurology and oncology.
Biosimilar drugmaker Alvotech (ALVO - Free Report) has positioned itself differently from other players in the space by using partnerships as its core commercial model. Rather than investing heavily in its own sales infrastructure, the company relies on distribution alliances to bring products to market across multiple regions. This model enables rapid expansion while allowing Alvotech to concentrate its resources on development and manufacturing.
The strategy seems to be working well for the company. In the first half of 2025, Alvotech’s product revenues surged more than 200% year over year to nearly $205 million. A significant portion of this growth came from the product revenues of its two immunology biosimilars — Simlandi (a biosimilar to AbbVie’s Humira) and Selarsdi (a biosimilar to J&J’s Stelara) — which are marketed in the United States by partner Teva Pharmaceuticals (TEVA - Free Report) . Alvotech has a similar partnership with Germany-based Stada to market biosimilar versions of Humira and Stelara under the names Hukyndra and Uzpruvo, respectively. Sales of both these products have rapidly scaled, helping Alvotech reaffirm its full-year 2025 revenue guidance of $600 million to $700 million.
These partnerships have also helped the company diversify income beyond product sales. ALVO has agreements with companies like Teva, Dr. Reddy’s Laboratories (RDY - Free Report) and Advanz Pharma that include upfront and milestone payments upon achieving regulatory approvals or reaching commercial milestones. Such incomes provide the company with a steadier cash position, which is especially valuable in the capital-intensive biosimilar business.
Diversification: The Next Move in ALVO’s Playbook?
The company is also making efforts to expand beyond the immunology space. Alvotech recently secured approval in the EU for Mynzepli, its biosimilar to Regeneron’s Eylea, through a partnership with Advanz Pharma. This marks its entry into ophthalmology, one of the fastest-growing therapeutic areas in the biosimilar landscape.
In addition, ALVO also expanded its partnerships with Dr. Reddy’s and Advanz Pharma, announcing plans to develop multiple biosimilar candidates across neurology and oncology. These include developing biosimilars for Novartis’ Kesimpta and Merck’s Keytruda, among others. Such strategic moves highlight how Alvotech is leveraging its alliance-driven model not only to scale existing products but also to build a broader, future-facing pipeline that could support sustained top-line momentum.
ALVO’s Price Performance, Valuation and Estimates
Shares of Alvotech have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, ALVO is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 3.23 times trailing sales, higher than 2.12 for the industry.
Image Source: Zacks Investment Research
Alvotech’s EPS estimates for 2025 and 2026 have improved significantly in the past 30 days.
Image Source: Zacks Investment Research
Alvotech currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Key Takeaways
Biosimilar drugmaker Alvotech (ALVO - Free Report) has positioned itself differently from other players in the space by using partnerships as its core commercial model. Rather than investing heavily in its own sales infrastructure, the company relies on distribution alliances to bring products to market across multiple regions. This model enables rapid expansion while allowing Alvotech to concentrate its resources on development and manufacturing.
The strategy seems to be working well for the company. In the first half of 2025, Alvotech’s product revenues surged more than 200% year over year to nearly $205 million. A significant portion of this growth came from the product revenues of its two immunology biosimilars — Simlandi (a biosimilar to AbbVie’s Humira) and Selarsdi (a biosimilar to J&J’s Stelara) — which are marketed in the United States by partner Teva Pharmaceuticals (TEVA - Free Report) . Alvotech has a similar partnership with Germany-based Stada to market biosimilar versions of Humira and Stelara under the names Hukyndra and Uzpruvo, respectively. Sales of both these products have rapidly scaled, helping Alvotech reaffirm its full-year 2025 revenue guidance of $600 million to $700 million.
These partnerships have also helped the company diversify income beyond product sales. ALVO has agreements with companies like Teva, Dr. Reddy’s Laboratories (RDY - Free Report) and Advanz Pharma that include upfront and milestone payments upon achieving regulatory approvals or reaching commercial milestones. Such incomes provide the company with a steadier cash position, which is especially valuable in the capital-intensive biosimilar business.
Diversification: The Next Move in ALVO’s Playbook?
The company is also making efforts to expand beyond the immunology space. Alvotech recently secured approval in the EU for Mynzepli, its biosimilar to Regeneron’s Eylea, through a partnership with Advanz Pharma. This marks its entry into ophthalmology, one of the fastest-growing therapeutic areas in the biosimilar landscape.
In addition, ALVO also expanded its partnerships with Dr. Reddy’s and Advanz Pharma, announcing plans to develop multiple biosimilar candidates across neurology and oncology. These include developing biosimilars for Novartis’ Kesimpta and Merck’s Keytruda, among others. Such strategic moves highlight how Alvotech is leveraging its alliance-driven model not only to scale existing products but also to build a broader, future-facing pipeline that could support sustained top-line momentum.
ALVO’s Price Performance, Valuation and Estimates
Shares of Alvotech have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, ALVO is trading at a premium to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 3.23 times trailing sales, higher than 2.12 for the industry.
Image Source: Zacks Investment Research
Alvotech’s EPS estimates for 2025 and 2026 have improved significantly in the past 30 days.
Image Source: Zacks Investment Research
Alvotech currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.